NeoPharm Announces FDA Grant Of Orphan Drug Designation For IL13-PE38QQR For The Treatment Of Idiopathic Pulmonary …
NeoPharm Announces FDA Grant Of Orphan Drug Designation For IL13-PE38QQR For The Treatment Of Idiopathic Pulmonary …
NeoPharm, Inc., announced today that the Officeof Orphan Products Development of the United States Food and Drug Administration (FDA) has granted orphan-drug designation for IL13-PE38QQR (IL13-PE) for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Dr. Aquilur Rahman, President and CEO, commented, “IPF is the most deadly disease of the lungs in humans with very high morbidity.
Read more on PharmaceuticalOnline
More Meth Drug Addiction Info:
- NeoPharm Submits Application for a Multicenter, Open-Label, Phase …
- USA FDA Bans two Dietary Weight-Loss Supplements | Weight Loss …
- Pleural Mesothelioma and Pleural Diseases | Thaipparambil.com
- AVANIR Pharmaceuticals Announces Zenvia Review Timeline …
- Why Would the FDA Allow Fen Phen? | Phentremine.org
- Cystoran New Drug Application News, 17 May 2010 | Health world
- An Exciting Upcoming 4Q09 for NeoPharm (OTC:NEOL) | The Market …
- NeoPharm receives FDA grant of orphan–drug designation for IPF …
- Alternative Medical News by NRC » Blog Archive » NeoPharm …
- NeoPharm, Inc. Announces Fourth Quarter And Full Year 2009 …